COMMUNIQUÉS West-GlobeNewswire

UNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results and Business Updates
14/05/2024
SOUTH SAN FRANCISCO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported [...]
Lowell Farms Inc. Announces Unaudited First Quarter 2024 Financial and Operational Results
14/05/2024
SALINAS, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Lowell Farms Inc. (the “Company”) (CSE: LOWL; OTCQX: LOWLF), a California cannabis company with advanced distribution and production capabilities including extraction, [...]
Psychemedics Corporation Reports First Quarter 2024 Financial Results
14/05/2024
DALLAS, May 14, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s leading provider of hair testing for drugs of abuse, today announced financial results for the first quarter ended March 31, [...]
Natural Alternatives International, Inc. Announces Fiscal 2024 Q3 and YTD Results
14/05/2024
CARLSBAD, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements, today announced [...]
Evoke Pharma Reports First Quarter 2024 Financial Results
14/05/2024
114% year-over-year increase in net product sales 70% prescriber growth in Q1 2024 compared to Q4 2023 Growing sales metrics reaffirms company’s $14M net revenue guidance for 2024 SOLANA BEACH, Calif., May 14, 2024 ( [...]
Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Closing Bell Series
14/05/2024
Live webcast on Thursday, May 16 th at 4:00 PM ET THE WOODLANDS, TX, May 14, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing [...]
Vincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
14/05/2024
Vincerx continued to progress Phase 1 dose-escalation studies for VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC), and VIP236, a first-in-class small molecule-drug conjugate (SMDC) The [...]
Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results
14/05/2024
Outcome from End-of-Phase 2 Meeting Supportive of a Placebo-Controlled Phase 3 Trial Updated 12 and 24-Month Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials Continue to Show Oral LUM-201 Achieves Significant [...]
NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer
14/05/2024
PARIS and CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic [...]
NANOBIOTIX annonce l'acceptation par l'Agence américaine du médicament, la FDA, d'un protocole pour une nouvelle étude randomisée de Phase 2 évaluant NBTXR3 pour les patients atteints d'un cancer du poumon de stade trois
14/05/2024
PARIS et CAMBRIDGE, Mass., 14 mai 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ : NBTX – la « Société »), société française de biotechnologie en phase de développement clinique avancé, pionnière des [...]
CooperCompanies to Participate in the William Blair Growth Stock Conference
14/05/2024
SAN RAMON, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, will participate in the William Blair Growth Stock Conference on Wednesday, June 5, 2024. Dan [...]
GENFIT Reports First Quarter 2024 Financial Information
14/05/2024
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 14, 2024 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients [...]
GENFIT : Information financière du premier trimestre 2024
14/05/2024
Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 14 mai 2024 – GENFIT (Nasdaq et Euronext : GNFT) , société biopharmaceutique de stade clinique avancé engagée dans l’amélioration de la vie des [...]
BioRestorative Therapies Provides First Quarter 2024 Business Update
14/05/2024
MELVILLE, N.Y., May 14, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) , a clinical stage company focused on stem cell-based therapies, today [...]
BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress
14/05/2024
Ozuriftamab vedotin (CAB-ROR2-ADC) Phase 2 data in squamous cell carcinoma of the head and neck (SCCHN) showed multiple confirmed responses and manageable safety profile; anticipate FDA meeting for SCCHN potential [...]
Singular Genomics Reports Recent Highlights and First Quarter 2024 Financial Results
14/05/2024
SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and [...]
QIAGEN receives European IVDR certification for QIAGEN Clinical Insight Interpret, its medical device software for clinical decision support
14/05/2024
As the first NGS interpretation platform for both oncology and hereditary applications, the updated version of QIAGEN Clinical Insight Interpret is approved for diagnostic use // Regulatory framework ensures greater [...]
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
14/05/2024
Announced positive proof of concept data from Phase 1 clinical trial of ELVN-001 in CML, achieving an initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients Strong balance sheet with $321 [...]
Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
14/05/2024
Initial Data from Ongoing MyPEAK™ - 1 Phase 1b of TN-201 Expected in Second Half of 2024 Clinical Sites Activated for RIDGE ™ -1 Phase 1b Clinical Trial of TN-401 Announced Cost Containment Measures in Alignment with [...]

Pages